Results 61 to 70 of about 9,620 (164)
Emerging Roles of PSTPIP2 in Autoimmunity: From Mechanism to Therapeutic Implications
Immunology, EarlyView.PSTPIP2 acts as a key brake on myeloid inflammation by suppressing IL‐1β‐driven signalling, macrophage dysregulation and inflammation‐associated bone remodelling. Its emerging roles in CRMO/CMO, rheumatoid arthritis, SAPHO syndrome and bullous pemphigoid support its potential as a biomarker and therapeutic target.
Erdong Zhang +9 more
wiley +1 more source
Is Canakinumab Safe During Pregnancy? New Insights from Three Cases in Slovakia
BiologicsBackground and Objectives: Canakinumab, a human recombinant monoclonal antibody against interleukin-1ß (IL-1ß), is indicated for the treatment of selected autoinflammatory periodic fever syndromes and rheumatic diseases.
Branislav Slenker +5 more
doaj +1 more source
Journal of Paediatrics and Child Health, EarlyView.ABSTRACT Aim The aim of this project was to develop and implement a working definition and ethical framework for use of innovative medicine in contemporary Australian paediatric practice. Methods A mixed methods research methodology was undertaken using a Delphi process to establish a definition of innovative medicines in paediatric patients.
Sonya Stacey +5 more
wiley +1 more source
Therapeutic Silencing of Tmprss6 Reduces Iron‐Induced Inflammation and Prolongs Survival in MDS Mice
American Journal of Hematology, Volume 101, Issue 9, Page 2105-2122, September 2026.ABSTRACT Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic disorders characterized by ineffective hematopoiesis, cytopenias, and an increased risk of progression to acute myeloid leukemia (AML). Despite advances in supportive and targeted therapies, disease‐modifying interventions remain limited.
Shahla Vilcassim +13 more
wiley +1 more source
Вопросы современной педиатрии, 2017 The article presents the follow-up of a patient with severe systemic juvenile idiopathic arthritis (JIA) resistant to glucocorticosteroids, to the first genetically engineered biologic drug (GEBD) tocilizumab, a monoclonal antibody to the interleukin (IL)
Ekaterina I. Alexeeva +2 more
doaj +1 more source
American Journal of Hematology, Volume 101, Issue 9, Page 2166-2176, September 2026.ABSTRACT Hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (alloHSCT) have both demonstrated remissions in VEXAS; however, comparative data is lacking. We conducted a multicenter, retrospective analysis of 66 patients diagnosed with VEXAS syndrome treated with HMA (n = 35) or alloHSCT (n = 31). Baseline characteristics
Saubia Fathima +48 more
wiley +1 more source
Cardiovascular disease incidence and cancer risk in two large European prospective cohorts
International Journal of Cancer, Volume 159, Issue 5, Page 1139-1152, 1 September 2026.What's new? Cardiovascular disease (CVD) and cancer share risk factors and biological mechanisms, raising questions about potential associations between the two, particularly regarding CVD duration and cancer onset. Whether CVD influences subsequent cancer risk, however, remains inconclusive.
Emma Fontvieille +25 more
wiley +1 more source
American Journal of Medical Genetics Part A, Volume 200, Issue 8, Page 1807-1813, August 2026.ABSTRACT Autosomal recessive loss‐of‐function variants in PPP1R13L cause an ultra‐rare cardiocutaneous syndrome characterized by rapidly progressive arrhythmogenic cardiomyopathy (ACM). PPP1R13L encodes iASPP, which has two potentially overlapping mechanisms driving ACM as both a regulator of NFκB‐mediated inflammation and a binding partner within the ...
Aaron Renberg +9 more
wiley +1 more source
Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
PharmaceuticalsBackground: Canakinumab, a humanized anti-IL-1β monoclonal antibody, is known for its ability to suppress IL-1β-mediated inflammation. However, continuous monitoring of its safety remains essential.
Weidong Zhang +5 more
doaj +1 more source
Canakinumab and cardiovascular outcomes: results of the CANTOS trial
Journal of Community Hospital Internal Medicine Perspectives, 2018 IL-1 cytokines are mainly responsible for controlling a series of pro-inflammatory reactions induced in response to pathogen mediated tissue injury. Among the IL-1 cytokine family, IL-1 β results in upregulation of genes responsible for boosting immune ...
Syed Raza Shah +6 more
doaj +1 more source